News Releases

Investor Alerts

Feb 1, 2021

IDEAYA to Participate in Upcoming February 2021 Investor Relations Events
Jan 19, 2021

Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
Jan 11, 2021

IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

IDE397 is being developed as a potential best-in-class MAT2A inhibitor for MTAP-deletion, which is prevalent in approximately 15% of all solid tumors
Jan 5, 2021

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor
Jan 4, 2021

IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences

Show per page